Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.08.2023 | Clinical study

Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

A modified dosage of nirmatrelvir/ritonavir based on estimated glomerular filtration rate (eGFR) is well tolerated for the treatment of mild COVID-19 infection in patients with chronic kidney disease (CKD), according to findings of a prospective study published in Clinical Infectious Diseases . …
Literatur
Zurück zum Zitat Chan GCK, et al. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19) Clinical Infectious Diseases : 2 Aug 2023. Available from: URL: http://doi.org/10.1093/cid/ciad371 Chan GCK, et al. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19) Clinical Infectious Diseases : 2 Aug 2023. Available from: URL: http://​doi.​org/​10.​1093/​cid/​ciad371
Metadaten
Titel
Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD
Publikationsdatum
01.08.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-44478-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Trastuzumab

Case report

Antineoplastics